Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal
antibody huC242, can block tumor growth in different ways. Some block the ability of tumor
cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them.
PURPOSE: This phase I trial is studying the side effects and best dose of maytansinoid
DM4-conjugated humanized monoclonal antibody huC242 in treating patients with solid tumors
that cannot be removed by surgery or have spread to other parts of the body.